Drugs / artemin
artemin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01842126 | Apr 2013 → Aug 2014 | radiculopathy | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01405833 | Jul 2011 → Sep 2012 | sciatica | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00961766 | Aug 2009 → Feb 2012 | sciatica | Biogen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01873404 | Jun 2013 → Mar 2015 | radiculopathy, sciatica | Biogen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-03-24 | Biogen | Results Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies biogen.com ↗
The functional recovery occurred even after a two-day delay in administering neublastin and lasted for more than six months. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-03-24 | Biogen | Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies biogen.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | artemin | “OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetics of single doses of BG00010 (neublastin, artemin, enovin) in subjects with unilateral sciatica.” PMID 25962165 ↗ May 2015 |
| Known as | BG00010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01842126 ↗ |
| Known as | enovin | “OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetics of single doses of BG00010 (neublastin, artemin, enovin) in subjects with unilateral sciatica.” PMID 25962165 ↗ May 2015 |
| Known as | Neublastin | “OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetics of single doses of BG00010 (neublastin, artemin, enovin) in subjects with unilateral sciatica.” PMID 25962165 ↗ May 20151“BG00010 (Neublastin)” NCT01405833 ↗ |
| Modality | Protein / enzyme biologic | “First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with...” PMID 25962165 ↗ May 2015 |
| Route | Intravenous | “intravenous BG00010 0.3, 1, 3, 10, 25, 50, 100, 200, 400, or 800 μg/kg, or subcutaneous BG00010 50 μg/kg” PMID 25962165 ↗ May 2015 |
| Route | Subcutaneous | “intravenous BG00010 0.3, 1, 3, 10, 25, 50, 100, 200, 400, or 800 μg/kg, or subcutaneous BG00010 50 μg/kg” PMID 25962165 ↗ May 2015 |